CannabisNewsWire
Editorial Coverage: Relatively insulated from economic cycles,
the innovation of today’s biotech companies puts them in a position
to potentially deliver outsized returns regardless of overall
conditions. Medicinal cannabis, a key sector in this industry, is
currently driving the largest returns, and it is on pace to exceed
US$50 billion in revenues by 2025. As more investors are noticing,
positive news continues to flow into the sector in terms of new
drug applications, product approvals and pipeline updates. For
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
(IMLFF
Profile), a preclinical-stage
biopharmaceutical company at the vanguard of cannabinoid-based
bio-pharmacology, market awareness of the company’s drug
development pipeline and biosynthesis technology has led to gains
of more than 400% over the last year. This level of activity places
InMed, currently valued at $100 million, among the ranks of larger
cannabis biotechs like GW Pharma (NASDAQ: GWPH), Zynerba
Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics, Inc.
(NASDAQ: CARA) and Isodiol International Inc.
(CSE: ISOL) (OTC: ISOLF).
Backed by mounting scientific data on the curative effects of
CBDs, specialty biotech companies have the opportunity to
capitalize on the explosive growth expected in the cannabis-derived
pharmaceutical market. The discovery of the human endocannabinoid
system dramatically changed both the understanding and the vast
potential of cannabinoid therapeutics, and thus has increased
acceptance and awareness of the potential of cannabinoids to affect
a much broader range of physiological functions than previously
considered. With a tsunami of innovation, cannabinoid
pharmaceutical companies now research, identify and develop new
drug candidates to create unique therapeutics to treat multiple
maladies and unmet medical needs.
InMed
Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) market
traction is based on the company’s proprietary cannabinoid
biosynthesis technology, one of three of its core assets and one
which serves as the base for its development of its drug-development
pipeline of novel therapeutics that leverage the
pharmacological benefits of cannabinoids like CBD. As TheSeedInvestor.com asked in a recent article, could
InMed be the “next big thing in cannabis?” (http://cnw.fm/JS9lv).
To date, most CBD research and drug development has focused on
the most easily isolated CBDs, but multiple curative opportunities
are believed to be found in the other 90+ cannabinoids of the
marijuana plant. InMed is the only known company with the ability
to isolate and bio-identically manufacture all of the
naturally occurring CBDs found in the cannabis sativa plant
(http://cnw.fm/5BfmB).
Conducted in-house, InMed’s cost-effective biosynthesis process
enhances the production, purification and quality control compared
to other chemical manufacturing methods, such as chemical
synthesis. InMed’s ability to produce its own pharmaceutical grade,
bio-identical CBDs also sets it apart from other companies that
rely on outside cultivators for their product supply.
In September, InMed filed a provisional patent to protect its
biosynthesis program (http://cnw.fm/B7PDd). Once the patent application is
converted into an international Patent Cooperation Treaty (PCT)
application and pursued in key jurisdictions throughout the world,
InMed will have significant commercial protection of its technology
as it explores the various ways it could have a medical impact on
important human diseases. Release of the patent filing sent shares
of InMed from $0.27 at market open to an intra-day high of $0.40 a
day later – with volume increasing roughly 8-fold to over 2.1
million for two consecutive days. Shares of InMed trading on the
U.S. OTC market have continued to climb and just recently clipped a
new 52-week high of $0.86.
It’s important to note that InMed’s market gains hinge on more
than its biosynthesis program. The company’s portfolio of
biomedical assets also includes a proprietary bioinformatics
assessment tool that enables the high-efficiency prediction of the
therapeutic potential and medicinal properties of individual CBDs
against particular medical conditions.
This computer-assisted system employs comprehensive algorithms
to integrate data from various bioinformatics databases, including
a vast database of the chemical structures of approved
pharmaceuticals, with InMed’s proprietary cannabinoid database and
know-how. This assessment tool, in combination with the company’s
biosynthesis technology and drug development pipeline, provides
InMed a competitive advantage and serves as its fundamental value
driver for drug discovery.
This unparalleled approach to cannabinoid production, research
and targeted drug development could be a game-changer for the
market, as many drug development efforts with synthetic derivatives
have failed. InMed’s production of CBDs identical to naturally
occurring compounds has already led to a growing pipeline of
potentially blockbuster drug candidates.
The company is currently developing two products in its drug
pipeline headed for clinical trials; INM-750, for the treatment of
Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.
Additionally, the company continues to advance its INM-405
candidate for the treatment of chronic and severe pain.
InMed’s INM-750 for Epidermolysis Bullosa, an orphan disease
characterized by extremely fragile skin, has potential global
market revenues estimated at $1 billion per year. Another candidate
in the pipeline, INM-085 for Glaucoma, has a global market
potential in excess of $5 billion, and the company’s development of
INM-405 targets the $36+ billion pain market.
In October, InMed provided an update on its pain program with
additional pre-clinical results suggesting that peripheral
application of certain CBD compounds, either alone or in
combination, is effective in the treatment of craniofacial muscle
pain disorders without any observed side effects to the central
nervous system (http://nnw.fm/1Os9A). With increased pressure for the
pharma industry to find non-addictive pain management alternatives
with limited side effects, InMed continues to research the
potential of non-THC cannabinoids to treat pain using a topical
formulation.
Leveraging its proprietary technologies, InMed is rapidly
expanding its pipeline of novel cannabinoid therapeutics for a
variety of medical conditions. Historically, biotech companies are
valued at about three times the peak annual sales of a company's
lead candidate. With a market cap around $100 million, InMed may be
significantly undervalued based on its capabilities.
Researching and developing cannabinoids for medical use since
1998 is cannabis biotech leader GW Pharma (NASDAQ:
GWPH). Focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas, GW Pharma has
only identified 15 of the 90+ CBDs in the cannabis plant, as noted
by TheSeedInvestor.com, and yet currently occupies a
market cap of over $3 billion.
GW Pharma commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex, which is approved for the
treatment of spasticity due to multiple sclerosis in numerous
countries outside the United States. The company has submitted an
NDA to the FDA for its leading development candidate, Epidiolex, a
formulation for the treatment of childhood-onset epilepsy disorders
like Lennox-Gastaut syndrome and Dravet syndrome. The company also
has several other product candidates in development for treating
glioblastoma, schizophrenia and epilepsy.
TheSeedInvestor.com also points out that Dr. Ado
Muhammed, chief medical officer of InMed and previously the
associate medical director at GW Pharmaceuticals, was instrumental
in leading GW Pharma when shares rose from less than $9 in 2013 to
more than $130 today.
Another biotech cannabis leader is Zynerba
Pharmaceuticals (NASDAQ: ZYNE), a clinical-stage specialty
pharmaceutical company focused on developing and commercializing
innovative pharmaceutically-produced transdermal cannabinoid
treatments. Zynerba’s ZYN002 CBD gel is the first and only
pharmaceutically produced CBD formulated as a patent-protected
permeation-enhanced gel and is being studied in children with
Fragile X Syndrome, adult epilepsy patients with focal seizures and
osteoarthritis. Currently trading around $12, shares of Zynerba
have ranged from $5.42-$25.95 over the last year, and the company
has a market valuation in excess of $160 million.
Trading between $9 and $28.50 over the last year with a market
cap near $430 million, Cara Therapeutics (NASDAQ:
CARA) is a clinical-stage biotech company looking to
change how pain is treated. Its portfolio includes opioid-based
products, anesthetic-based drugs and analgesics that seek to
alleviate itch and pain. Cara is developing a new class of medicine
called Kappa Opioid Receptor Agonists (KORAs). KORAs target a
completely different receptor in the body, the kappa opioid
receptor, to treat pain in a fundamentally new way. The company’s
lead pipeline product, CR845, is a peripherally acting KORAs. To
date, CR845 has shown in phase 2 clinical trials promising pain
relief without many of the traditional side effects of opioids and
NSAIDs.
Isodiol International (CSE: ISOL) (OTC: ISOLF)
is a leader in pharmaceutical and nutraceutical grade phytochemical
(plant-based) compounds and an industry leader in the manufacturing
and development of phytoceutical consumer products. Isodiol is one
of the world’s largest sources for phyto-cannabinoids and offers
high quality, bioactive products from seed to finished product.
Isodiol was one of the first to commercialize 99%+ pure, bioactive
pharmaceutical grade cannabinoids, micro-encapsulations and
nanotechnology for high quality consumable and topical skin care
products. Isodiol’s growth strategy includes the development of
over-the-counter and pharmaceutical drugs, expanding its
phytoceutical portfolio and continued international expansion.
Trading around $1.15 per share, Isodiol has a 52-week range of
$0.05 to $1.69 and carries $380+ million market capitalization.
Historically, the biotechnology sector has been volatile but it
also has delivered some of the market’s greatest returns.
Cannabinoid biotechs now lead the way in the sector and, as
research continues, a myriad of compounds may soon be developed to
unlock a vast range of new therapeutics that could benefit millions
of ailing people. New-found cannabinoid therapeutics have the
potential to create a bonanza in the biotech sector and early
investors could reap extraordinary returns.
As more investors plot their way through biotech opportunities,
an increasing number of them recognize the potential value of
cannabis-focused contenders like InMed pursuing ways to apply CBDs
to treat unmet medical needs.
For more information on InMed Pharmaceuticals, please visit:
InMed
Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, CNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. CNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, CNW brings
its clients unparalleled visibility, recognition and brand
awareness. CNW is where news, content and information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Nov 2023 to Nov 2024
